ADAP
Price
$0.28
Change
-$0.00 (-0.00%)
Updated
Jul 18 closing price
Capitalization
74.08M
16 days until earnings call
AKBA
Price
$3.86
Change
-$0.02 (-0.52%)
Updated
Jul 18 closing price
Capitalization
1.01B
10 days until earnings call
Interact to see
Advertisement

ADAP vs AKBA

Header iconADAP vs AKBA Comparison
Open Charts ADAP vs AKBABanner chart's image
Adaptimmune Therapeutics
Price$0.28
Change-$0.00 (-0.00%)
Volume$616.45K
Capitalization74.08M
Akebia Therapeutics
Price$3.86
Change-$0.02 (-0.52%)
Volume$3.05M
Capitalization1.01B
ADAP vs AKBA Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. AKBA commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and AKBA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (ADAP: $0.28 vs. AKBA: $3.86)
Brand notoriety: ADAP and AKBA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 100% vs. AKBA: 60%
Market capitalization -- ADAP: $74.08M vs. AKBA: $1.01B
ADAP [@Biotechnology] is valued at $74.08M. AKBA’s [@Biotechnology] market capitalization is $1.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 6 TA indicator(s) are bullish while AKBA’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 6 bullish, 4 bearish.
  • AKBA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than AKBA.

Price Growth

ADAP (@Biotechnology) experienced а +4.06% price change this week, while AKBA (@Biotechnology) price change was -1.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

AKBA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($1.01B) has a higher market cap than ADAP($74.1M). AKBA YTD gains are higher at: 103.158 vs. ADAP (-48.116). AKBA has higher annual earnings (EBITDA): 6.59M vs. ADAP (-50.18M). AKBA has more cash in the bank: 113M vs. ADAP (59.6M). ADAP has less debt than AKBA: ADAP (48.7M) vs AKBA (54.1M). AKBA (185M) and ADAP (180M) have equivalent revenues.
ADAPAKBAADAP / AKBA
Capitalization74.1M1.01B7%
EBITDA-50.18M6.59M-762%
Gain YTD-48.116103.158-47%
P/E RatioN/AN/A-
Revenue180M185M97%
Total Cash59.6M113M53%
Total Debt48.7M54.1M90%
FUNDAMENTALS RATINGS
ADAP vs AKBA: Fundamental Ratings
ADAP
AKBA
OUTLOOK RATING
1..100
971
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6436
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (51) in the Biotechnology industry is in the same range as AKBA (77). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (36) in the Biotechnology industry is in the same range as ADAP (64). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAKBA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KBAGF5.45N/A
N/A
Koninklijke BAM Groep NV
RADLY2.55N/A
N/A
Raia Drogasil SA
SILS0.14N/A
N/A
Silver Scott Mines, Inc.
SSBP9.10N/A
N/A
SSB Bancorp Inc.
PCRDF11.65N/A
N/A
PCA Corp.

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+1.08%
AKBA - ADAP
41%
Loosely correlated
-0.52%
AUTL - ADAP
33%
Poorly correlated
-0.41%
ATXS - ADAP
33%
Poorly correlated
-5.69%
CSLLY - ADAP
32%
Poorly correlated
+3.71%
NTLA - ADAP
32%
Poorly correlated
+1.94%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ADAP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ADAP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-0.52%
ADAP - AKBA
42%
Loosely correlated
+1.08%
IPSC - AKBA
40%
Loosely correlated
+0.10%
XERS - AKBA
39%
Loosely correlated
-2.29%
FHTX - AKBA
39%
Loosely correlated
+0.49%
HOWL - AKBA
38%
Loosely correlated
+0.71%
More